CD130 rather than CD126 expression is associated with disease activity in multiple myeloma.
We analysed the expression of both components of IL-6R, CD126 the ligand binding protein and CD130 the signal transducing protein, on plasma cells from MGUS and multiple myeloma (MM) cases using flow cytometry. CD126 was detectable in 50% of either MGUS or MM patients without any change of expression during disease progression. In contrast, CD130 expression was up-regulated during tumoural expansion (43% of MM patients at diagnosis versus 88% at relapse). Finally, combining CD126 and CD130 expression we found a significant increase of the percentage of CD126+ CD130+ patients at relapse, underlying the crucial role of IL-6 response in the late stage of MM.
Barillé
S
S
INSERM U463 and Laboratoire d'Hématologie, Institut de Biologie, Nantes, France.
Thabard
W
W
Robillard
N
N
Moreau
P
P
Pineau
D
D
Harousseau
J L
JL
Bataille
R
R
Amiot
M
M
D015703:Antigens, CD / Q000378:metabolism*; D050822:Cytokine Receptor gp130; D005434:Flow Cytometry; D006801:Humans; D008562:Membrane Glycoproteins / Q000378:metabolism*; D009101:Multiple Myeloma / Q000235:genetics*; D011379:Prognosis; D019947:Receptors, Interleukin-6 / Q000378:metabolism*; D012008:Recurrence
D015703:Antigens, CD; C494199:IL6ST protein, human; D008562:Membrane Glycoproteins; D019947:Receptors, Interleukin-6; D050822:Cytokine Receptor gp130